A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
A phase 2 trial of Tremelimumab, Durvalumab, Bevacizumab in hepatocellular carcinoma, run by MedImmune LLC, active and no longer recruiting.
Overview
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT02519348 by MedImmune LLC, with 433 participants enrolled, started 2015-10-19 and due to reach its primary completion in 2020-11-06. Interventions recorded: Tremelimumab, Durvalumab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDurvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
Shares Tremelimumab, Durvalumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
Shares Tremelimumab, Durvalumab, AstraZeneca, Hepatocellular carcinoma.
- TrialAssess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Shares Durvalumab, Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Durvalumab, Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Shares Tremelimumab, Durvalumab, AstraZeneca, Hepatocellular carcinoma.
- TrialPhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Shares Tremelimumab, Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab and Tremelimumab for Pediatric Malignancies
Shares Tremelimumab, Durvalumab, AstraZeneca.
- TrialTreatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Shares Tremelimumab, Durvalumab, AstraZeneca.